BioMarin Pharmaceutical shares are trading higher after Bernstein upgraded the stock to Outperform, raising Voxzogo 2032 sales estimates and saying it expects management to lay out a margin expansion path.
Portfolio Pulse from Benzinga Newsdesk
BioMarin Pharmaceutical shares rose following an upgrade by Bernstein to 'Outperform'. The firm increased its sales estimates for Voxzogo by 2032 and anticipates BioMarin's management to outline a strategy for margin expansion.
August 20, 2024 | 5:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioMarin Pharmaceutical's stock price increased after Bernstein upgraded it to 'Outperform'. The upgrade was based on higher sales estimates for Voxzogo by 2032 and expected margin expansion strategies.
The upgrade by Bernstein to 'Outperform' is a positive signal to investors, likely leading to increased buying interest. The raised sales estimates for Voxzogo and expected margin expansion provide a strong growth outlook, further supporting the stock's upward movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100